

CDC Core Elements	Additional IDSA Criteria
<p><b>Leadership Commitment:</b> Dedicating necessary human, financial and information technology resources.</p> <p><i>The 2019 update has additional examples of hospital leadership, and the examples are stratified by “priority” and “other”.</i></p>	<p>Hospital Mission Statement, if it specifically mentions Antimicrobial Stewardship as a priority.</p> <p>Letter of attestation from Division Chief or C-Suite Executive reflecting leadership commitment and assigned accountability.</p> <p>Print out/screenshot of facility’s website that shows leadership title.</p>
<p><b>Accountability:</b> Appoint a leader or co-leaders, such as a physician and pharmacist, responsible for program management and outcomes.</p> <p><i>The 2019 update highlights the effectiveness of the physician and pharmacy co-leadership, which was reported by 59% of the hospitals responding to the 2019 NHSN Annual Hospital Survey.</i></p>	<p>Represents having ID Physician Leadership of the ASP, who receive protected time or compensation for their leadership.</p>
<p><b>Pharmacy Expertise (previously “Drug Expertise”):</b> Appoint a pharmacist, ideally as the co-leader of the stewardship program, to lead implementation efforts to improve antibiotic use.</p> <p><i>This Core Element was renamed “Pharmacy Expertise” to reflect the importance of pharmacy engagement for leading implementation efforts to improve antibiotic use.</i></p>	<p>Represents having Drug Expertise with ID-trained Pharmacist</p> <ul style="list-style-type: none"> <li>▪ PharmD with <b>one</b> of the following: <ul style="list-style-type: none"> <li>• Three years of clinical pharmacy experience AND AS training course certificate (SIDP/MAD-ID course) AND a letter of endorsement from ID Physician</li> <li>• Completed PGY-1 Residency AND AS training course certificate (SIDP/MAD-ID course)</li> <li>• PGY-2 Residency in ID</li> <li>• ID fellowship</li> </ul> </li> </ul>
<p><b>Action:</b> Implement interventions, such as prospective audit and feedback or preauthorization, to improve antibiotic use.</p> <p><i>The 2019 update has additional examples of interventions which are stratified to “priority” and “other”. The “other” interventions are</i></p>	<p>Has established protocols, consistent with reporting on antibiotic use and resistance patterns to clinicians, and proven interventions that effectively optimize antimicrobial use.</p>

<p><i>categorized as infection based, provider-based, pharmacy-based, microbiology-based, and nursing based interventions.</i></p>	
<p><b>Tracking:</b> Monitor antibiotic prescribing, impact of interventions, and other important outcomes like C. difficile infection and resistance patterns.</p> <p><i>It is important for hospitals to electronically submit antibiotic use data to the National Healthcare Safety Network (NHSN) Antimicrobial Use (AU) Option for monitoring and benchmarking inpatient antibiotic use.</i></p>	
<p><b>Reporting:</b> Regularly report information on antibiotic use and resistance to prescribers, pharmacists, nurses, and hospital leadership.</p> <p><i>The 2019 update points out the effectiveness of provider level data reporting, while acknowledging that this has not been well studied for hospital antibiotic use.</i></p>	<p>Demonstrate effective use of EHR and/or Clinical Decision Support System (CDSS) system as an integral component of the ASP.</p> <ul style="list-style-type: none"> <li>▪ Produces reports on overall antibiotic use and trends (antibiotic use measured by using defined daily dosing (DDD) or days of therapy (DOT)).</li> <li>▪ Produces reports on ASP interventions accepted and actions taken (e.g., percentage of cases where therapy is appropriate, adherence to hospital-specific guidelines, frequency at which de-escalation occurs, appropriate cultures obtained before starting antibiotics, timely administration of appropriate antibiotics for those cases of suspected sepsis, and performance of antibiotic time-outs), and measures of appropriate use and outcome measures such as length of stay, risk-adjusted mortality, hospital-onset <i>C. difficile</i> infection rates, adverse drug reactions, and antibiotic-resistance (focusing on hospital onset cases).</li> </ul>
<p><b>Education:</b> Educate prescribers, pharmacists, and nurses about adverse reactions from antibiotics, antibiotic resistance and optimal prescribing.</p> <p><i>The 2019 update highlights that case-based education through prospective audit and feedback and preauthorization are effective methods to provide education on antibiotic use. This can be especially powerful when the case-based education is provided in person (e.g., handshake stewardship).</i></p>	

